Abstract
Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systematic overview was conducted by searching PubMed, Medline, and The Cochrane Library up to January 2019. Study selection and data extraction: All English-language clinical trials and case reports related to the efficacy of ceftaroline in new, not-yet-approved FDA indications in MRSA infections in pediatric or adult populations. Data synthesis: In the case of MRSA bacteremia (MRSAB) infections, three different randomized studies in pediatric patients showed effectiveness of ceftaroline. When used in the case of adult populations with MRSA bacteremia, a small trial of 16 patients showed 50% clinical success in patients with acute bacterial skin and skin structure infections versus 63% clinical success in patients with community-acquired bacterial pneumonia. Another case series of six refractory case reports showed 50% clinical success of ceftaroline in patients with MRSA. Conclusions: Although there are few case reports and limited data to date, ceftaroline fosamil should continue to be studied as an alternative therapy in MRSA infections in both pediatric and adult populations. Clinical success rates of ceftaroline were, in most cases, considered high when treating patients with MRSA infection. More clinical trials need to be studied. In the specific case of MRSA bacteremia, the treatment options remain few and ceftaroline should be extensively studied for the salvage treatment of MRSAB.
Highlights
Ceftaroline is a novel cephalosporin, given to patients by intravenous (IV) infusion
We will discuss new applications of ceftaroline for the treatment ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus resistant Staphylococcus aureus (MRSA) in both adult and pediatric populations based on new case of MRSA in both adult and pediatric populations based on new case reports, clinical trials and other reports, clinical trials and other observational studies reported in literature
Ceftaroline fosamil was approved by the Food and Drug Administration (FDA) in 2016 for pediatric patients from 2 months to 18 years of age to treat two specific indications: Acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia CABP
Summary
Ceftaroline is a novel cephalosporin, given to patients by intravenous (IV) infusion It is the active form of ceftaroline fosamil, a bactericidal antibiotic with Gram-positive and -negative coverage. 600 mg intravenous (IV) every 12 h ceftaroline fosamil compared to ceftriaxone 1 g IV every 24 h for 5 to 7 days for treatment of hospitalized CAP patients, but did not include patients with methicillinhospitalized CAP patients, but did not include patients with methicillin-resistant Staphylococcus aureus resistant Staphylococcus aureus (MRSA) infections. Two studies reported the isolation of MRSA microorganisms from pediatric patients in literature and their MIC ranges show to be considered susceptible to ceftaroline (Table 1) [13,14] Based on this evidence, more research needs to be conducted to evaluate ceftaroline susceptibility testing against isolated MRSA strains in pediatrics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
